MedTrace Logo

Tumor Response in Hypofractionated Radiotherapy

NCT02854449 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-04-20

No results posted yet for this study

Summary

This study will follow-up different immune cell populations in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of Local Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.

Conditions

  • Neoplasms

Sponsors & Collaborators

  • Beijing Tongren Hospital

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Gao Xianshu, Master · Peking University First Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854449 on ClinicalTrials.gov